Delcath Systems: Funding, Investors & Team (Sep 2026)
Delcath Systems specializes in the treatment of metastatic liver cancer through interventional oncology. Their distinct product, Melphalan Hydrochloride for Injection, is used in conjunction with the Delcath Hepatic Delivery System (Melphalan/HDS) to deliver targeted high-dose chemotherapy to the liver while minimizing systemic exposure.
Delcath Systems has raised $140M across 3 funding rounds on record, the most recent an undisclosed round of $35.0M announced in Sep 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Delcath Systems Company Profile and Key Stats
Latest funding round on record: Sep 2023.
Delcath Systems Funding Rounds
Delcath Systems raised $20.0M in a Post-IPO Debt announced in Aug 2021.
1.6 years later, an undisclosed round of $85.0M was announced in Mar 2023.
6 months later, an undisclosed round of $35.0M was announced in Sep 2023.
Delcath Systems Founders and Leadership Team
Contact details for the Delcath Systems team: 2 of 2 have an email address on file.
Start 14-day free trial →Delcath Systems Funding Compared to Other Biotechnology Startups
Delcath Systems' latest round of $35.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Delcath Systems in Biotechnology and New York
Companies Similar to Delcath Systems
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Delcath Systems Funding FAQs
What does Delcath Systems do?
Delcath Systems specializes in the treatment of metastatic liver cancer through interventional oncology. Their distinct product, Melphalan Hydrochloride for Injection, is used in conjunction with the Delcath Hepatic Delivery System (Melphalan/HDS) to deliver targeted high-dose chemotherapy to the liver while minimizing systemic exposure.
How much funding has Delcath Systems raised?
Delcath Systems has raised $140M across 3 rounds on record. The most recent is an undisclosed round of $35.0M announced in Sep 2023.
When did Delcath Systems last raise funding?
Delcath Systems' most recent funding round on record is an undisclosed round of $35.0M, announced in Sep 2023.
Who founded Delcath Systems?
FundedIQ lists Roger Stoll (Founder) at Delcath Systems.
Who is the CEO of Delcath Systems?
Gerard Michel is listed as CEO at Delcath Systems.
Where is Delcath Systems headquartered?
Delcath Systems is based in New York, United States.
How many employees does Delcath Systems have?
Delcath Systems is in the 51-100 employee band.
How does Delcath Systems' funding compare to other Biotechnology startups?
Delcath Systems' latest round of $35.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Delcath Systems Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Delcath Systems is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.